TG6050
AXP000096.1 · Oncolytic virus
- Platform
- vaccinia virus (Copenhagen)
- Originator
- Transgene
- Sponsor
- Transgene
Names
| Name | Type | Source |
|---|---|---|
| TG6050 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- Copenhagen
- Replication
- conditionally replicating
- Modifications
- thymidine kinase (J2R) deleted; further deletions not confirmed
- Transgenes
- IL12A, IL12B, anti-CTLA-4 antibody
- Route
- intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C200558
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05788926 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Terminated | Phase 1 | 2023-04-05 | 2025-06-23 | 22 | Non-small Cell Lung Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39060022 | TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. | Journal for immunotherapy of cancer | 2024 | cited by trial NCT05788926 |
Notes
Intravenous oncolytic vaccinia carrying IL-12 and a full-length anti-CTLA-4 antibody; phase 1 in NSCLC (NCT05788926) terminated 2025.
How to cite
TG6050 (AXP000096.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000096.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.